ClinicalTrials.gg
CompletedNCT00634660Updated Feb 1, 2017

Safety and Tolerability Study of rAvPAL-PEG to Treat Phenylketonuria

A Phase 1 interventional study of rAvPAL-PEG in Phenylketonuria, sponsored by BioMarin Pharmaceutical. Completed at 8 sites in United States. Open to participants aged 16 Years to 50 Years. Per ClinicalTrials.gov, last updated 2017-02-01.

Sponsored by BioMarin Pharmaceutical · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2009, 17 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
16 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing pegvaliase in Phenylketonurias — 1 open to participants now, 2 under way, 1 of them phase 3. pegvaliase · Phenylketonurias.

Enrollment
7th of 10
25 · median 39
Started
2008
the only one that year
Phase 1
Only one
of the 10
Registered
1st of 10
by date
Lead sponsor
10 of 10
BioMarin Pharmaceutical

Among the 10 studies testing pegvaliase in Phenylketonurias, this one is the 7th largest by enrollment, is the only one that started in 2008, is the only one in phase 1, and was the 1st registered.

Phenylketonurias

191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.

Browse Phenylketonurias studies →

Open to participants now

1 of the 10 studies testing pegvaliase in Phenylketonurias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About pegvaliase

pegvaliase: first FDA approval 2018 (PALYNZIQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 16 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing pegvaliase in Phenylketonurias, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and tolerability of injections of rAvPAL-PEG in subjects with PKU.

Read the detailed description

This is a Phase 1, open-label, single-dose study in approximately 35 subjects with PKU who are 16 to 50 years old. Seven cohorts are planned, each consisting of 5 subjects; the cohorts as planned are 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. Increasing doses of rAvPAL-PEG will be assessed sequentially until the final dose is evaluated or any of the stopping criteria are reached. Subjects will each receive a single dose and then will be followed for a total of 42 days (6 weeks) with visits to the clinical research unit (CRU) as specified in the Schedule of Events Toxicity will be measured according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, v 3).

03

Conditions studied

  • Phenylketonuria

Browse trials for

04

Who can participate

Ages eligible
16 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of PKU with both of the following:
  • Current blood Phe concentration of ≥600 µmol/L at Screening.
  • Average blood Phe concentration of ≥600 µmol/L over the past 3 years, using available data.
  • Willing and able to provide written, signed , or, in the case of participants under the age of 18, provide written assent (if required) and written informed consent by a parent or legal guardian, after the nature of the study has been explained, and prior to any research-related procedures.
  • Willing and able to comply with all study procedures.
  • Between the ages of 16 and 50 years, inclusive.
  • Females of must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to Screening, or who have had total hysterectomy.
  • Sexually active subjects must be willing to use an acceptable method of while participating in the study.
  • Stable diet with no significant modifications during the 4 weeks preceding the administration of study drug.
  • In generally good health as evidenced by physical examination, clinical laboratory evaluations (hematology, chemistry, and urinalysis), and (ECG) at Screening.

Exclusion criteria

Exclusion Criteria:

  • Use of any product or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
  • Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) or to breastfeed at any time during the study.
  • Concurrent disease or condition that would interfere with study participation or safety (eg, history or presence of cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, oncologic, or psychiatric disease).
  • Any condition that, in the view of the Principal Investigator (PI), places the subject at high risk of poor treatment compliance or of not completing the study.
  • Known to rAvPAL PEG or its .
  • (ALT) concentration > 2 times the .
  • Creatinine above the upper limit of normal.
  • Donation of blood or plasma within 30 days prior to the administration of study drug.
  • Use of any over-the-counter (OTC) medication, including vitamins, within 7 days prior to the administration of study drug, without evaluation and approval by the Investigator.
  • Use of any prescription medication within 14 days prior to the administration of study drug without evaluation and approval by the Investigator.
  • Treatment with any drug known to affect hepatic enzyme activity, including (but not limited to) barbiturates, phenothiazines, cimetidine, or carbamazepine, within 30 days prior to study drug administration.
  • Use of any tobacco products within 60 days prior to study drug administration.
  • Positive urine screen for use of nicotine (cotinine) or drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine, cannabinoids, and opiates).
  • Positive test or has been treated for , , or (HIV).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Active comparator
    0.001 mg/kg

    One subcutaneous injection of 0.001 mg/kg of rAvPAL-PEG.

    Drug: rAvPAL-PEG

  • Active comparator
    0.003 mg/kg

    One subcutaneous injection of 0.003 mg/kg of rAvPAL-PEG.

    Drug: rAvPAL-PEG

  • Active comparator
    0.01 mg/kg

    One subcutaneous injection of 0.01 mg/kg of rAvPAL-PEG.

    Drug: rAvPAL-PEG

  • Active comparator
    0.03 mg/kg

    One subcutaneous injection of 0.03 mg/kg of rAvPAL-PEG.

    Drug: rAvPAL-PEG

  • Active comparator
    0.1 mg/kg

    One subcutaneous injection of 0.1 mg/kg of rAvPAL-PEG.

    Drug: rAvPAL-PEG

  • Active comparator
    0.3 mg/kg

    One subcutaneous injection of 0.3 mg/kg of rAvPAL-PEG.

    Drug: rAvPAL-PEG

  • Active comparator
    1.0 mg/kg

    One subcutaneous injection of 1.0 mg/kg of rAvPAL-PEG.

    Drug: rAvPAL-PEG

Interventions

  • rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.

06

What researchers measure

Primary outcomes

  1. • To assess the incidence of treatment-emergent adverse events of a single, subcutaneous (SC) injections of rAvPAL-PEG in subjects with PKU.

    Specifically, safety was to be assessed by examining the incidence of all treatment-emergent adverse events reported during the study period and clinically significant changes in vital signs and clinical laboratory results, including development of rAvPAL-PEG antibodies.

    Time frame: 6 weeks

Secondary outcomes

  1. • To evaluate the pharmacokinetics (PK) of single, SC injections of rAvPAL-PEG administered at escalating doses, in subjects with PKU.

    Specifically, exposure, AUC- and Cmax -dose proportionality, Tmax , λz and t1/2

    Time frame: 6 weeks

  2. • To evaluate the effect of different dose levels of rAvPAL-PEG on blood Phe concentrations in subjects with PKU.

    Specifically, exposure, AUC- and Cmax -dose proportionality, Tmax , λz and t1/2

    Time frame: 6 weeks

07

Study locations

8 sites
  • Children's Memorial Hospital
    Chicago, Illinois 60614, United States
  • University of Minnesota Medical Center-Fairview
    Minneapolis, Minnesota 55455, United States
  • Washington University Center for Applied Research Sciences
    St. Louis, Missouri 63110, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
  • University of Utah Hospital
    Salt Lake City, Utah 84132, United States
  • University of Wisconsin
    Madison, Wisconsin 53705, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Apr 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2008
First posted
Mar 13, 2008
Start
May 2008
Primary completionActual
Apr 2009
CompletionActual
Oct 2009
Last update
Feb 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00634660
Responsible party
Sponsor
First posted
Mar 13, 2008
Start date
May 2008
Primary completion
Apr 2009
Completion
Oct 2009
Last update
Feb 1, 2017

Study contacts

Celeste Decker, MD
study director · BioMarin Pharmaceutical

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegvaliase

Start the discussion